Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 315-318

  Mehmet Turk, H ^a   Camci, Celalettin ^a   Sevinc, Alper ^a   Bukyukberber, Suleyman ^b   Sari, Ibrahim ^a   Adli, Mustafa ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

COX 2; Cyclooxygenase 2; Immunohistochemistry; Lung cancer; Turkey

Indexed keywords

CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ENZYME IMMUNOASSAY; ENZYMOLOGY; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84864865485     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.315     Document Type: Article

References (29)

1. Achiwa H, Yatabe Y, Hida T, et al (1999). Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res, 5, 1001-5 .
2. Altorki NK, Keresztes RS, Port JL, et al (2003). Celecoxib,a selective cyclo-oxygenase-2 infibitor,enhances the response to preoperative paclitaxel and carboplatin in early-stage non small cell lung cancer. J Clin Oncol, 21, 2645-50.
3. Brabender J, Park J, Metzger R, et al (2002). Prognostic significance of cyclooxygenase 2 mRNA expression in non small cell lung cancer. Ann Surg, 235, 440-3.
4. Castelao JE, Bart RD 3rd, DiPerna CA, et al (2003). Lung cancer and cyclooxygenase-2. Ann Thorac Surg, 76, 1327-35.
5. Denkert C, Köbel M, Pest S, et al (2002). Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carsinoma. Am J Pathol, 160, 893-903.
6. Duperron C, Castonguay A (1997). Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carsinogenesis, 18, 1001-6.
7. Edelman MJ, Watson D, Wang X, et al(2008). Eicosanoid modulation in advenced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-- Cancer and Leukemia Group B Trial 30203. J Clin Oncol, 26, 848-55.
8. Fidler MJ, Argiris A, Patel JD, et al (2008). The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinid and celecoxib. Clin Cancer Res, 14, 2088-94.
9. Harris RE, Beebe-Donk J, Schuller HM (2002). Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep, 9, 693-5.
10. Hida T, Kozaki K, Muramatsu H, et al (2000). Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res, 6, 2006-11.
11. Hida T, Yatabe Y, Achiwa H, et al (1998). Incresed expression of cyclooxygenase 2 occurs frequently in human lung cancers , specifically in adenocarsinomas. Cancer Res, 58, 3761-4.
12. Khuri FR, Wu H, Lee JJ, et al (2001). Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non small cell lung cancer. Clin Cancer Res, 7, 861-7.
13. Masferrer JL, Leahy KM, Koki AT, et al (2000). Antiangigenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.
14. Mascaux C, Martin B, Paesmans M, et al (2006). Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer, 9, 139-45.
15. Marrogi AJ, Travis WD, Welsh JA, et al (2000). Nitric oxide synthase, cyclooxigenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res, 6, 4739-44.
16. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, et al (2000). Antiangigenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.
17. Mountain CF (2002). Staging classşfication of lung cancer. A critical evaluation. Clin Chest Med, 23, 103-21.
18. Milas L, Kishi K, Hunter N, et al (1999). Enhancemant of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst, 91, 1501-4.
19. Nie D, Honn KV (2002). Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci, 59, 799-807.
20. Ranger GS, Thomas V, Jewell A, et al (2004). Elevated cyclooxygenase-2 expression correlates with distant metastates in breast cancer. Anticancer Res, 24, 2349-51.
21. Ristimäki A, Sivula A, Lundin J, et al (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res, 62, 632-5.
22. Schreinemachers DM, Everson RB (1994). Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology, 5, 138-46.
23. Sinicrope FA, Gill S (2004). Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev, 23, 63-75.
24. Smith WL, Langenbach R (2001). Why there are two cyclooxygenase isozymes. J Clin Invest, 107, 1491-5.
25. Trifan OC, Durham WF, Salazar VS, et al (2002). Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT- 11. Cancer Res, 62, 5778-84.
26. Travis WD, Travis LB, Devesa SS (1995). Lung cancer. Cancer, 75, 191-202.
27. Tsubochi H, Sato N, Hiyama M, et al (2006). Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in non-small cell lung cancer. Ann Thorac Surg, 82, 1198-204.
28. Yao R, Rioux N, Castonguay A, et al (2000). Inhibition of COX-2 and induction of apoptosis: two determinants of antiinflammatory drugs chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res, 26, 731-42.
29. Zimmermann KC, Sarbia M, Weber AA, et al (1999). Cyclooxygenase-2 expresion in human esophageal carsinoma. Cancer Res, 59, 198-204.